Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions
Asthma
Interventions
DRUG

Active

A 5 mg single dose given intravenously via syringe pump over 1 minute.

DRUG

Placebo

Same as active

Trial Locations (2)

27704

Duke Asthma, Allergy and Airway Center, Durham

80206

National Jewish Health, Denver

Sponsors
All Listed Sponsors
lead

Nivalis Therapeutics, Inc.

INDUSTRY

NCT01316315 - Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma | Biotech Hunter | Biotech Hunter